North China Pharmaceutical Co Ltd (600812):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:North China Pharmaceutical Co Ltd (600812) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8073
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
North China Pharmaceutical Co Ltd (NCPC), a subsidiary of North China Pharmaceutical Group Corp is a pharmaceutical company that develops, produces and sells novel drugs and pharmaceutical related products. The company offers preparation products, nutrition, pharmaceutical raw materials and intermediates, pesticide and veterinary products, among others. It offers products in the dosage forms of granules, capsules, and tablets. NCPC offers integration and management services. The company sells its products in through a network of distributors in China and abroad. NCPC is headquartered in Shijiazhuang, Hebei, China.

North China Pharmaceutical Co Ltd (600812) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
Debt Offering 11
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 11
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 12
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 13
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 14
North China Pharma Announces Public Offering Of Notes For US$73 Million 15
Acquisition 16
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 16
North China Pharmaceutical Co Ltd – Key Competitors 17
North China Pharmaceutical Co Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 11
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 12
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 13
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 14
North China Pharma Announces Public Offering Of Notes For US$73 Million 15
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 16
North China Pharmaceutical Co Ltd, Key Competitors 17
North China Pharmaceutical Co Ltd, Other Locations 18
North China Pharmaceutical Co Ltd, Subsidiaries 18

List of Figures
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
North China Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[North China Pharmaceutical Co Ltd (600812):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Allscripts Healthcare Solutions, Inc.:企業のM&A・事業提携・投資動向
    Allscripts Healthcare Solutions, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allscripts Healthcare Solutions, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Flint Group SA:企業の戦略的SWOT分析
    Flint Group SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Gevo Inc (GEVO):企業の財務・戦略的SWOT分析
    Summary Gevo Inc (Gevo) is a renewable chemicals and advanced biofuels company that offers renewable chemicals and biofuels. The company’s products include carbon cycle products, low carbon renewable jet fuels, renewable gasoline, isobutanol blendstocks, ingredient products, animal feed and proteins …
  • Himatsingka Seide Ltd:企業の戦略・SWOT・財務情報
    Himatsingka Seide Ltd - Strategy, SWOT and Corporate Finance Report Summary Himatsingka Seide Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • China Resources Pharmaceutical Group Ltd (3320)-製薬・医療分野:企業M&A・提携分析
    Summary China Resources Pharmaceutical Group Ltd (CR Pharma), a subsidiary of China Resources (Holdings) Co Ltd is a pharmaceutical company that offers nutritional supplements. The company offers research and development, manufacture, and distribution of whole drug products. Its products comprise ch …
  • Aldi Inc:企業の戦略的SWOT分析
    Aldi Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • ESI Group S.A. (ESI):企業の財務・戦略的SWOT分析
    ESI Group S.A. (ESI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Nordic Nanovector ASA (NANO):企業の財務・戦略的SWOT分析
    Summary Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of haematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed fo …
  • Vistin Pharma AS (VISTIN):製薬・医療:M&Aディール及び事業提携情報
    Summary Vistin Pharma AS (Vistin), a subsidiary of Vistin Pharma ASA is a healthcare company that produces and supplies active pharmaceutical ingredients and solid dosage forms. The company’s products include opioids, an analgesics and antitussive; metformin, an API for the treatment of diabetes II; …
  • Genuine Parts Company (GPC):企業の財務・戦略的SWOT分析
    Genuine Parts Company (GPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Natura Cosmeticos SA:戦略・SWOT・企業財務分析
    Natura Cosmeticos SA - Strategy, SWOT and Corporate Finance Report Summary Natura Cosmeticos SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Iconic Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Iconic Therapeutics Inc (Iconic Therapeutics) is a biopharmaceutical company that provides translation of scientific insight into breakthrough medicines. The company offers development of tissue factor in angiogenesis, inflammation, and metastasis that led to develop new approach to retinal …
  • WGL Holdings Inc (WGL)-石油・ガス分野:企業M&A・提携分析
    Summary WGL Holdings, Inc. (WGL) is an energy holding company that delivers natural gas, and provides energy-related products and services to customers. It also provides design-build energy efficient and sustainable solutions and water and energy-related infrastructure services. The company delivers …
  • Ingredia Nutritional:企業の戦略・SWOT・財務情報
    Ingredia Nutritional - Strategy, SWOT and Corporate Finance Report Summary Ingredia Nutritional - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Homeland Energy Solutions, LLC:企業の戦略的SWOT分析
    Homeland Energy Solutions, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • New China Life Insurance Company Ltd.:企業の戦略・SWOT・財務分析
    New China Life Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report Summary New China Life Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Pakistan Refinery Ltd (PRL):企業の財務・戦略的SWOT分析
    Pakistan Refinery Ltd (PRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Hal Trust
    Hal Trust - Strategy, SWOT and Corporate Finance Report Summary Hal Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • American Greetings Corporation:企業の戦略・SWOT・財務情報
    American Greetings Corporation - Strategy, SWOT and Corporate Finance Report Summary American Greetings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Pitney Bowes Inc.:企業の戦略・SWOT・財務情報
    Pitney Bowes Inc. - Strategy, SWOT and Corporate Finance Report Summary Pitney Bowes Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆